Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Romain Rouzier"'
Autor:
Alaa Cheikhelard, Maud Bidet, Amandine Baptiste, Magali Viaud, Christine Fagot, Naziha Khen-Dunlop, Christine Louis-Sylvestre, Sabine Sarnacki, Philippe Touraine, Caroline Elie, Yves Aigrain, Michel Polak, Jean-Luc Brun, Emile Darai, Philippe Descamps, Karinne Gueniche, Pierre Leguevaque, Patrice Lopes, Claude Louis-Borrione, Karine Morcel, Chloe Ouallouche, Bernard-Jean Paniel, Aline Ranke, Romain Rouzier, Catherine Pienkowski
Publikováno v:
American Journal of Obstetrics and Gynecology. 219:281.e1-281.e9
Vaginal agenesis in Mayer-Rokitansky-Küster-Hauser syndrome can be managed either by various surgeries or dilation. The choice still depends on surgeon's preferences rather than on quality comparative studies and validated protocols.We sought to com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d6cdea9f1e6214b7e54218fe7c44791
https://doi.org/10.1016/j.ajog.2018.07.015
https://doi.org/10.1016/j.ajog.2018.07.015
Autor:
Sofiene Jaziri, Nathalie Lassau, Alain Roche, Jean-Rémi Garbay, Michele Lamuraglia, Jérome Leclère, Marie-Christine Mathieu, Romain Rouzier
Publikováno v:
European Journal of Radiology. 56:376-381
Introduction The aim of this study was to determine the efficacy of Doppler ultrasonography (US) with perfusion software and contrast agent injection (DUPC) during radiofrequency (RF) treatment of local recurrent breast cancer. Materials and Methods
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bdb858fe30b8367463d488733d17e2be
https://doi.org/10.1016/j.ejrad.2005.06.003
https://doi.org/10.1016/j.ejrad.2005.06.003
Autor:
Marisol Urbieta, Eric Leblanc, Paul Cottu, Elisabeth Chereau, Christophe Pomel, Romain Rouzier, Sebastien Gouy, Sarah Zohar, Julien Dupin, Leila Kockler, Sabine Balouet, Florence Joly, Eric Lambaudie, Rose-Marie Ferri, Anne Floquet, Frédéric Selle
Publikováno v:
Journal of Clinical Oncology. 35:5538-5538
5538 Background: ANTHALYA showed that neoadjuvant Bevacizumab (B) added to Carboplatin and Paclitaxel (CP) was well tolerated and achieved encouraging complete resection rates at IDS (58.6%) in unresectable FIGO stage IIIC/IV ovarian, tubal or perito
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c2f1318a252903a49c155ceb44344c3
https://doi.org/10.1200/jco.2017.35.15_suppl.5538
https://doi.org/10.1200/jco.2017.35.15_suppl.5538